JP2020172535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020172535A5 JP2020172535A5 JP2020116636A JP2020116636A JP2020172535A5 JP 2020172535 A5 JP2020172535 A5 JP 2020172535A5 JP 2020116636 A JP2020116636 A JP 2020116636A JP 2020116636 A JP2020116636 A JP 2020116636A JP 2020172535 A5 JP2020172535 A5 JP 2020172535A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- lymphoma
- substituted
- fibrosis
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 COc1ccccc1C(NCC(C=C1)=CCC1c1n[n](C2CC2)c(*N)c1C(N)=O)=O Chemical compound COc1ccccc1C(NCC(C=C1)=CCC1c1n[n](C2CC2)c(*N)c1C(N)=O)=O 0.000 description 12
- FURWRYDMHKIPCD-UHFFFAOYSA-N CC(C)(CC1)CCC1[n](c(N)c1C(N)=O)nc1-c1ccc(CNC(c(cccc2)c2OC)=O)cc1 Chemical compound CC(C)(CC1)CCC1[n](c(N)c1C(N)=O)nc1-c1ccc(CNC(c(cccc2)c2OC)=O)cc1 FURWRYDMHKIPCD-UHFFFAOYSA-N 0.000 description 1
- WAMIWWRAQHHIFM-UHFFFAOYSA-N CC(C)N(CC1[n](c(N)c2C(N)=O)nc2-c2ccc(CNC(c3cc(F)ccc3OC)=O)cc2)CC1(F)F Chemical compound CC(C)N(CC1[n](c(N)c2C(N)=O)nc2-c2ccc(CNC(c3cc(F)ccc3OC)=O)cc2)CC1(F)F WAMIWWRAQHHIFM-UHFFFAOYSA-N 0.000 description 1
- OGZZPXMMRMETQL-UHFFFAOYSA-N CC(CC1)(CCC1[n](c(N)c1C(N)=O)nc1-c1ccc(CNC(c(cccc2)c2OC)=O)cc1)O Chemical compound CC(CC1)(CCC1[n](c(N)c1C(N)=O)nc1-c1ccc(CNC(c(cccc2)c2OC)=O)cc1)O OGZZPXMMRMETQL-UHFFFAOYSA-N 0.000 description 1
- RDQGZEZFBQBVIO-UHFFFAOYSA-N CC1(C=CC=CC1OC)C(NCc(cc1)ccc1-c(c(C(N)=O)c1N)n[n]1-c1cc(C)ccc1)=O Chemical compound CC1(C=CC=CC1OC)C(NCc(cc1)ccc1-c(c(C(N)=O)c1N)n[n]1-c1cc(C)ccc1)=O RDQGZEZFBQBVIO-UHFFFAOYSA-N 0.000 description 1
- JZQDGEJAEPKVGK-UHFFFAOYSA-N CC[n](c(N)c1C(N)=O)nc1-c1ccc(CNC(c(cc(cc2)F)c2OC)=O)cc1 Chemical compound CC[n](c(N)c1C(N)=O)nc1-c1ccc(CNC(c(cc(cc2)F)c2OC)=O)cc1 JZQDGEJAEPKVGK-UHFFFAOYSA-N 0.000 description 1
- UZONARPHOQPNEY-UHFFFAOYSA-N CN(C)C(C(CC1)CCC1[n](c(N)c1C(N)=O)nc1-c1ccc(CNC(c(cccc2)c2OC)=O)cc1)=O Chemical compound CN(C)C(C(CC1)CCC1[n](c(N)c1C(N)=O)nc1-c1ccc(CNC(c(cccc2)c2OC)=O)cc1)=O UZONARPHOQPNEY-UHFFFAOYSA-N 0.000 description 1
- MEBBGZAFWHMPNM-UHFFFAOYSA-N COc(c(C(NCc(cc1)ccc1-c1n[n](C(COC2)C2(F)F)c(N)c1CN)=O)c1)ccc1F Chemical compound COc(c(C(NCc(cc1)ccc1-c1n[n](C(COC2)C2(F)F)c(N)c1CN)=O)c1)ccc1F MEBBGZAFWHMPNM-UHFFFAOYSA-N 0.000 description 1
- WLRCPRUFXLOORH-UHFFFAOYSA-N COc(c(C(NCc(cc1)ccc1C(C1C(N)=O)=NN(C(C2CCCC2)C(F)(F)F)C1N)=O)c1)ccc1F Chemical compound COc(c(C(NCc(cc1)ccc1C(C1C(N)=O)=NN(C(C2CCCC2)C(F)(F)F)C1N)=O)c1)ccc1F WLRCPRUFXLOORH-UHFFFAOYSA-N 0.000 description 1
- LAXXDERKUSIJDS-MSUUIHNZSA-N COc(cccc1)c1C(N/C=C1/C=CC(c2n[n](C(CC3)c4c3cccc4)c(N)c2C(N)=O)=CC1)=O Chemical compound COc(cccc1)c1C(N/C=C1/C=CC(c2n[n](C(CC3)c4c3cccc4)c(N)c2C(N)=O)=CC1)=O LAXXDERKUSIJDS-MSUUIHNZSA-N 0.000 description 1
- VRWALNOIQXJOQE-UHFFFAOYSA-N COc(cccc1)c1C(NCc(cc1)ccc1-c1n[n](C(C2)Cc3c2cccc3)c(N)c1C(N)=O)=O Chemical compound COc(cccc1)c1C(NCc(cc1)ccc1-c1n[n](C(C2)Cc3c2cccc3)c(N)c1C(N)=O)=O VRWALNOIQXJOQE-UHFFFAOYSA-N 0.000 description 1
- NOPTVQQJNWYPKJ-UHFFFAOYSA-N COc(cccc1)c1C(NCc(cc1)ccc1-c1n[n](C(CC2)CCC2OCc2ccccc2)c(N)c1C(N)O)=O Chemical compound COc(cccc1)c1C(NCc(cc1)ccc1-c1n[n](C(CC2)CCC2OCc2ccccc2)c(N)c1C(N)O)=O NOPTVQQJNWYPKJ-UHFFFAOYSA-N 0.000 description 1
- RXOAFCGAWUXBRJ-UHFFFAOYSA-N COc1ccccc1C(NCc(cc1)ccc1-c(c(C(N)O)c1N)n[n]1-c1cccc(F)c1)=O Chemical compound COc1ccccc1C(NCc(cc1)ccc1-c(c(C(N)O)c1N)n[n]1-c1cccc(F)c1)=O RXOAFCGAWUXBRJ-UHFFFAOYSA-N 0.000 description 1
- ZEMFIILRYIPVGZ-UHFFFAOYSA-N COc1ccccc1C(NCc(cc1)ccc1-c1n[n](C(CC2)CCC2O)c(N)c1C(N)=O)=O Chemical compound COc1ccccc1C(NCc(cc1)ccc1-c1n[n](C(CC2)CCC2O)c(N)c1C(N)=O)=O ZEMFIILRYIPVGZ-UHFFFAOYSA-N 0.000 description 1
- QCRCLFBYNOGRAQ-UHFFFAOYSA-N COc1ccccc1C(NCc(cc1)ccc1-c1n[n](CCc2nnn[nH]2)c(N)c1C(N)=O)=O Chemical compound COc1ccccc1C(NCc(cc1)ccc1-c1n[n](CCc2nnn[nH]2)c(N)c1C(N)=O)=O QCRCLFBYNOGRAQ-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022092275A JP7419437B2 (ja) | 2015-12-16 | 2022-06-07 | キナーゼ阻害剤として有用な化合物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522245.8A GB201522245D0 (en) | 2015-12-16 | 2015-12-16 | Compounds useful as kinase inhibitors |
| GB1522245.8 | 2015-12-16 | ||
| GB1613945.3 | 2016-08-15 | ||
| GBGB1613945.3A GB201613945D0 (en) | 2016-08-15 | 2016-08-15 | Compounds useful as kinase inhibitors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532035A Division JP6731483B2 (ja) | 2015-12-16 | 2016-12-16 | キナーゼ阻害剤として有用な化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022092275A Division JP7419437B2 (ja) | 2015-12-16 | 2022-06-07 | キナーゼ阻害剤として有用な化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020172535A JP2020172535A (ja) | 2020-10-22 |
| JP2020172535A5 true JP2020172535A5 (https=) | 2021-02-18 |
| JP7086140B2 JP7086140B2 (ja) | 2022-06-17 |
Family
ID=57590725
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532035A Active JP6731483B2 (ja) | 2015-12-16 | 2016-12-16 | キナーゼ阻害剤として有用な化合物 |
| JP2020116636A Active JP7086140B2 (ja) | 2015-12-16 | 2020-07-06 | キナーゼ阻害剤として有用な化合物 |
| JP2022092275A Active JP7419437B2 (ja) | 2015-12-16 | 2022-06-07 | キナーゼ阻害剤として有用な化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532035A Active JP6731483B2 (ja) | 2015-12-16 | 2016-12-16 | キナーゼ阻害剤として有用な化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022092275A Active JP7419437B2 (ja) | 2015-12-16 | 2022-06-07 | キナーゼ阻害剤として有用な化合物 |
Country Status (38)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
| JP7337502B2 (ja) | 2015-09-16 | 2023-09-04 | ロクソ オンコロジー， インコーポレイテッド | がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体 |
| CN114716381B (zh) | 2015-12-16 | 2025-03-11 | 洛克索肿瘤学股份有限公司 | 可用作激酶抑制剂的化合物 |
| GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
| WO2019195810A2 (en) * | 2018-04-06 | 2019-10-10 | Praxis Biotech LLC | Atf6 inhibitors and uses thereof |
| JP6995195B2 (ja) | 2018-05-18 | 2022-02-04 | 富士フイルム株式会社 | ３－ジフルオロメチルピラゾール化合物の製造方法及び３－ジフルオロメチルピラゾール－４－カルボン酸化合物の製造方法、並びに、ピラゾリジン化合物 |
| CN117285467A (zh) * | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021053234A1 (en) * | 2019-09-19 | 2021-03-25 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Compounds and compositions for treating kidney disease |
| CN110724135B (zh) * | 2019-11-18 | 2023-04-28 | 上海医药工业研究院有限公司 | 一种艾拉普林中间体及其制备方法 |
| JP7142173B2 (ja) | 2019-12-06 | 2022-09-26 | ロクソ オンコロジー， インコーポレイテッド | ブルトン型チロシンキナーゼ阻害剤の投薬 |
| MX2022008148A (es) | 2020-01-02 | 2022-07-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidores de btk. |
| WO2021180107A1 (en) * | 2020-03-12 | 2021-09-16 | Fochon Pharmaceuticals, Ltd. | Compounds useful as kinase inhibitors |
| TW202317099A (zh) * | 2020-09-10 | 2023-05-01 | 美商絡速藥業公司 | 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體 |
| CN112386597B (zh) * | 2020-10-15 | 2022-03-15 | 天津济坤医药科技有限公司 | 泽布替尼在制备治疗肺纤维化疾病药物中的应用 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN116348453B (zh) * | 2021-04-25 | 2025-07-04 | 烨辉医药科技(上海)有限公司 | 杂芳族甲酰胺化合物及其用途 |
| WO2022240920A1 (en) * | 2021-05-14 | 2022-11-17 | Loxo Oncology, Inc. | Cocrystalline forms of a bruton's tyrosine kinase inhibitor |
| JP2024524480A (ja) * | 2021-07-01 | 2024-07-05 | ハンチョウ、ヘルズン、セラピューティクス、カンパニー、リミテッド | ブルトン型チロシンキナーゼ及びその突然変異体の分解剤、組成物並びにそれらの応用 |
| CN115611810B (zh) * | 2021-07-16 | 2025-03-04 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑类化合物及包含该化合物的组合物及其用途 |
| KR20240157639A (ko) | 2021-12-14 | 2024-11-01 | 크로스파이어 온콜로지 홀딩 비.브이. | 거대고리 btk 억제제 |
| WO2023143355A1 (en) * | 2022-01-28 | 2023-08-03 | Hansoh Bio Llc | Azacycle amide derivative, preparation methods and medicinal uses thereof |
| JP2025508964A (ja) * | 2022-03-03 | 2025-04-10 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | シクロアルキルまたはヘテロシクリルで置換されたヘテロアリール化合物、並びにその組成物及び使用 |
| EP4493557A4 (en) * | 2022-03-18 | 2026-03-18 | Insilico Medicine Ip Ltd | PYRAZOLE MEMBRANE-ASSOCIATED CDC2-SPECIFIC TYROSINE AND THREONINE KINASE INHIBITORS (PKMYT1) AND THEIR USES |
| CN115894376B (zh) * | 2022-12-15 | 2025-05-16 | 南京雷正医药科技有限公司 | 一种芳香族酰胺类化合物、药物组合物及其用途 |
| IL322630A (en) | 2023-02-22 | 2025-10-01 | Assia Chem Ind Ltd | Solid forms of pirobrutinib |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
| WO2024246287A1 (en) | 2023-06-02 | 2024-12-05 | Crossfire Oncology Holding B.V. | Medical use of a macrocyclic reversible btk inhibitor |
| WO2024256568A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Salt and crystal forms of a macrocyclic btk inhibitor |
| WO2024256574A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Process for preparing macrocyclic btk inhibitors |
| KR20250046558A (ko) | 2023-09-27 | 2025-04-03 | 임창섭 | 5g 사물인터넷 기반 하드월렛 간의 디지털자산 안심이체 시스템 |
| WO2025124496A1 (zh) * | 2023-12-13 | 2025-06-19 | 正大天晴药业集团股份有限公司 | 含有吡唑环和双环杂芳基的化合物、其药物组合物及用途 |
| WO2025137329A1 (en) * | 2023-12-22 | 2025-06-26 | Neupharma, Inc | Certain chemical entities, compositions, and methods |
| CN119059974B (zh) * | 2024-08-12 | 2025-10-28 | 武汉九州钰民医药科技有限公司 | 一种吡托布鲁替尼的制备方法 |
| CN119059973A (zh) * | 2024-08-12 | 2024-12-03 | 武汉九州钰民医药科技有限公司 | 一种吡托布鲁替尼的合成工艺 |
| CN120504661B (zh) * | 2025-07-14 | 2025-11-07 | 复旦大学 | Alkbh8小分子抑制剂及其制备方法和用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| JP2003509428A (ja) | 1999-09-17 | 2003-03-11 | アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー | 治療薬としてのピラゾロピリミジン |
| US6291504B1 (en) * | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
| US20030225098A1 (en) | 2002-03-21 | 2003-12-04 | Hirst Gavin C. | Kinase inhibitors |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| EP2068869A4 (en) * | 2006-10-06 | 2011-05-25 | Abbott Lab | NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE |
| CA2668286C (en) | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| SG10202107066WA (en) | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| CA2730930C (en) | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| PT2324008E (pt) * | 2008-07-24 | 2012-06-25 | Nerviano Medical Sciences Srl | 3,4-diarilpirazoles como inibidores da proteína quinase |
| US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| EP2588465B1 (en) | 2010-06-30 | 2017-01-25 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| PL2710005T3 (pl) | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
| ES2770550T3 (es) | 2011-05-17 | 2020-07-02 | Univ California | Inhibidores de quinasa |
| JP2014520863A (ja) | 2011-07-13 | 2014-08-25 | ファーマサイクリックス，インク． | Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤 |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2013191965A1 (en) | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
| WO2014022569A1 (en) | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
| SG11201500499TA (en) * | 2012-08-10 | 2015-03-30 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| GB201214750D0 (en) * | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| KR101668574B1 (ko) * | 2012-11-02 | 2016-10-24 | 화이자 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
| CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| KR102272792B1 (ko) * | 2013-09-30 | 2021-07-05 | 광저우 이노케어 파마 테크 씨오., 엘티디. | Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도 |
| WO2015075051A1 (en) * | 2013-11-19 | 2015-05-28 | Universitaet Des Saarlandes | Allosteric inhibitors of atypical protein kinases c |
| WO2015095099A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
| GB201404987D0 (en) | 2014-03-20 | 2014-05-07 | Redx Pharma Ltd | Compounds |
| CN105085474B (zh) * | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| GB201410430D0 (en) * | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
| TN2017000329A1 (en) | 2015-01-28 | 2019-01-16 | Bayer Pharma AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| GB2548542A (en) * | 2015-06-16 | 2017-09-27 | Redx Pharma Plc | Compounds |
| JP7337502B2 (ja) | 2015-09-16 | 2023-09-04 | ロクソ オンコロジー， インコーポレイテッド | がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体 |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| KR20180095871A (ko) | 2015-12-16 | 2018-08-28 | 프리오스타 피티와이 엘티디 | 덴드리머 및 그의 배합물 |
| LT3390390T (lt) | 2015-12-16 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui |
| TW201725203A (zh) | 2015-12-16 | 2017-07-16 | 必治妥美雅史谷比公司 | 作為ａｐｊ受體促效劑之雜芳基羥基嘧啶酮 |
| CN108367243B (zh) | 2015-12-16 | 2021-09-28 | 艺康美国股份有限公司 | 用于膜过滤清洁的过氧甲酸组合物 |
| CN114716381B (zh) | 2015-12-16 | 2025-03-11 | 洛克索肿瘤学股份有限公司 | 可用作激酶抑制剂的化合物 |
-
2016
- 2016-12-16 CN CN202210310724.0A patent/CN114716381B/zh active Active
- 2016-12-16 HU HUE16816363A patent/HUE051921T2/hu unknown
- 2016-12-16 IL IL285976A patent/IL285976B2/en unknown
- 2016-12-16 RS RS20201291A patent/RS60982B9/sr unknown
- 2016-12-16 CN CN202210311970.8A patent/CN114573510B/zh active Active
- 2016-12-16 CN CN202111022492.0A patent/CN113636978B/zh active Active
- 2016-12-16 CN CN202210312076.2A patent/CN114621146A/zh active Pending
- 2016-12-16 CO CONC2018/0006164A patent/CO2018006164A2/es unknown
- 2016-12-16 ES ES20194724T patent/ES3041897T3/es active Active
- 2016-12-16 US US16/063,542 patent/US10695323B2/en active Active
- 2016-12-16 CN CN202111022488.4A patent/CN113603645B/zh active Active
- 2016-12-16 PE PE2018001143A patent/PE20181449A1/es unknown
- 2016-12-16 CN CN202210312064.XA patent/CN114605327B/zh active Active
- 2016-12-16 MA MA055064A patent/MA55064A/fr unknown
- 2016-12-16 JP JP2018532035A patent/JP6731483B2/ja active Active
- 2016-12-16 CA CA3008488A patent/CA3008488C/en active Active
- 2016-12-16 WO PCT/GB2016/053968 patent/WO2017103611A1/en not_active Ceased
- 2016-12-16 CR CR20180367A patent/CR20180367A/es unknown
- 2016-12-16 EA EA201891268A patent/EA035132B1/ru not_active IP Right Cessation
- 2016-12-16 SG SG10202012498TA patent/SG10202012498TA/en unknown
- 2016-12-16 AU AU2016373530A patent/AU2016373530B2/en active Active
- 2016-12-16 MA MA49809A patent/MA49809A1/fr unknown
- 2016-12-16 TN TNP/2018/000213A patent/TN2018000213A1/en unknown
- 2016-12-16 NZ NZ743553A patent/NZ743553A/en unknown
- 2016-12-16 UA UAA202003795A patent/UA127863C2/uk unknown
- 2016-12-16 ES ES16816363T patent/ES2828431T3/es active Active
- 2016-12-16 CN CN202210311995.8A patent/CN114634447B/zh active Active
- 2016-12-16 CN CN202210312050.8A patent/CN114591242B/zh active Active
- 2016-12-16 KR KR1020187020225A patent/KR102215792B1/ko active Active
- 2016-12-16 PE PE2021001581A patent/PE20220507A1/es unknown
- 2016-12-16 UA UAA201807294A patent/UA122258C2/uk unknown
- 2016-12-16 SI SI201630920T patent/SI3390395T1/sl unknown
- 2016-12-16 KR KR1020217003683A patent/KR20210018530A/ko not_active Withdrawn
- 2016-12-16 LT LTEP16816363.2T patent/LT3390395T/lt unknown
- 2016-12-16 MD MDE20181001T patent/MD3390395T2/ro unknown
- 2016-12-16 MY MYPI2022003990A patent/MY200590A/en unknown
- 2016-12-16 EP EP20194724.9A patent/EP3782994B1/en active Active
- 2016-12-16 CN CN201680073031.7A patent/CN108473481B/zh active Active
- 2016-12-16 MX MX2021003478A patent/MX394193B/es unknown
- 2016-12-16 PE PE2021001592A patent/PE20220502A1/es unknown
- 2016-12-16 DK DK16816363.2T patent/DK3390395T3/da active
- 2016-12-16 MX MX2018007267A patent/MX380907B/es unknown
- 2016-12-16 EP EP16816363.2A patent/EP3390395B1/en active Active
- 2016-12-16 PT PT168163632T patent/PT3390395T/pt unknown
- 2016-12-16 HR HRP20201835TT patent/HRP20201835T1/hr unknown
- 2016-12-16 MY MYPI2022003989A patent/MY202026A/en unknown
- 2016-12-16 SG SG11201805044WA patent/SG11201805044WA/en unknown
-
2018
- 2018-06-10 IL IL259923A patent/IL259923B/en active IP Right Grant
- 2018-06-13 PH PH12018501268A patent/PH12018501268A1/en unknown
- 2018-06-14 CL CL2018001591A patent/CL2018001591A1/es unknown
- 2018-06-20 ZA ZA2018/04137A patent/ZA201804137B/en unknown
- 2018-08-22 US US16/109,162 patent/US10342780B2/en active Active
- 2018-08-27 US US16/113,661 patent/US10464905B2/en active Active
-
2020
- 2020-05-13 US US15/930,657 patent/US10918622B2/en active Active
- 2020-05-28 ZA ZA2020/03176A patent/ZA202003176B/en unknown
- 2020-07-06 JP JP2020116636A patent/JP7086140B2/ja active Active
- 2020-07-26 IL IL276283A patent/IL276283B/en active IP Right Grant
- 2020-11-16 CY CY20201101090T patent/CY1123561T1/el unknown
- 2020-12-15 US US17/122,103 patent/US11471441B2/en active Active
-
2021
- 2021-01-26 ZA ZA2021/00544A patent/ZA202100544B/en unknown
- 2021-02-24 IL IL281067A patent/IL281067B/en unknown
- 2021-03-23 AU AU2021201811A patent/AU2021201811B2/en active Active
- 2021-08-31 AU AU2021225162A patent/AU2021225162B2/en active Active
- 2021-08-31 AU AU2021225161A patent/AU2021225161B2/en active Active
- 2021-10-05 ZA ZA2021/07471A patent/ZA202107471B/en unknown
- 2021-10-05 ZA ZA2021/07472A patent/ZA202107472B/en unknown
- 2021-11-12 US US17/525,350 patent/US11826351B2/en active Active
-
2022
- 2022-06-07 JP JP2022092275A patent/JP7419437B2/ja active Active
-
2023
- 2023-07-31 US US18/362,249 patent/US12220401B2/en active Active
-
2024
- 2024-02-27 HU HUS2400003C patent/HUS2400003I1/hu unknown
- 2024-02-29 LU LU00330C patent/LUC00330I2/fr unknown
- 2024-02-29 NO NO2024008C patent/NO2024008I1/no unknown
- 2024-03-01 FI FIC20240004C patent/FIC20240004I1/fi unknown
- 2024-03-04 FR FR24C1009C patent/FR24C1009I2/fr active Active
- 2024-03-04 CY CY2024003C patent/CY2024003I1/el unknown
- 2024-03-06 NL NL301262C patent/NL301262I2/nl unknown
- 2024-03-06 LT LTPA2024506C patent/LTPA2024506I1/lt unknown
- 2024-11-21 US US18/955,844 patent/US20250090500A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020172535A5 (https=) | ||
| JP2018538307A5 (https=) | ||
| ES2985528T3 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades | |
| RU2632915C2 (ru) | Производные пиридинона и пиридазинона | |
| JP6506845B2 (ja) | Ｂ型肝炎ウイルス感染症の治療及び予防のための新規テトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類 | |
| RU2014121074A (ru) | Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона | |
| KR20210096123A (ko) | Nlrp 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물 | |
| US11377450B2 (en) | Functionalized heterocycles as antiviral agents | |
| JP2022507506A5 (https=) | ||
| CN102753547A (zh) | 三唑并吡啶衍生物 | |
| JP2019518071A5 (https=) | ||
| EP3099685A1 (en) | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | |
| JP2021513551A (ja) | 複素環式化合物、その応用及びそれを含有する医薬組成物 | |
| CN105209460A (zh) | 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物 | |
| CA2732192A1 (en) | Substituted pyridines, and use thereof as gsk3 inhibitors | |
| SI3087075T1 (en) | SYK INHIBITORS | |
| JP2015518899A5 (https=) | ||
| CA2944187C (en) | Prodrugs of hiv reverse transcriptase inhibitors | |
| WO2021055425A2 (en) | Functionalized heterocycles as antiviral agents | |
| US20240327388A1 (en) | Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals | |
| JP2024507253A5 (https=) | ||
| US20220274928A1 (en) | Papd5 inhibitors and methods of use thereof | |
| JP2021501219A5 (https=) | ||
| US20250026769A1 (en) | Papd5 inhibitors and methods of use thereof | |
| CN102858769A (zh) | 吡唑并吡啶激酶抑制剂 |